Fitzpatrick Institute for Photonics Fitzpatrick Institute for Photonics
Pratt School of Engineering
Duke University
 HOME > pratt > FIP    Search Help Login pdf version printable version 

Publications of Michael R. Zalutsky    :chronological  alphabetical  combined  bibtex listing:

Papers Published

  1. DeGrado TR, Zalutsky MR, Coleman RE, Vaidyanathan G. Effects of specific activity on meta-[131I]iodobenzylguanidine kinetics in isolated rat heart. Nucl. Med. Biol., 1998; 25:59-64
  2. Foulon CF, Alston KL, Zalutsky MR: Astatine-211 label ed biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy. Nucl Med Biol 1998, 25:81-88
  3. Cunningham, SH, Mairs RJ, Wheldon TE, Welsh PC, Vaidyanathan G, Zalutsky MR. Radiotoxicity to neuroblastoma cells and spheroids of beta-, alpha- and Auger electron-emitting conjugates of benzylguanidine. Br J Cancer 1998; 77:2061-2068
  4. Hauk ML, Zalutsky MR. The effects of hyperthermia on the catabolism of a radioiodinated chimeric monoclonal antibody. Clinical Cancer Res 1998; 4:2071-2077
  5. Larsen, RH, Akabani G, Welsh P, Zalutsky MR. The cytotoxicity and microdosimetry of 211AT-labeled chimeric monoclonal antibodies on human glioma and melanoma cells in vitro. Radiation Res. 1998; 149:155-162
  6. Hauck ML, Larsen RH, Welsh PC, Zalutsky MR. Cytotoxicity of a-particle emitting 211At-labeled antibody in tumor spheroids: no effect of hyperthermia. Br J Cancer, 1998; 77:753-759
  7. Larsen RH, Akabani G, Welsh P, Zalutsky MR. The cytotoxicity and microdosimetry of 211At-labeled chimeric monoclonal antibodies on human glioma and melanoma cells in vitro. Radiation Res., 1998; 149:155-162
  8. Larsen, RH, Slade S, Zalutsky MR. Blocking [211At] astatide accumulation in normal tissues: evaluation of seven potential compounds. Nucl Med Biol 1998; 25: 351-357
  9. Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon II, JE, Vick NA, Paleologos N, Cokgor I, Zalutsky MR. Iodine-131-labeled anti-tenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results. J Clin Oncol. 1998: 16:2202-2212
  10. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD. The class III variant of the epidermal growth factor receptor (EGFRvIII): Characterization and utilization as an immunotherapeutic target. J NeuroVirol. 1998;4:148-158
  11. Vaidyanathan G, Zalutsky MR. Preparation of 5-[131I]iodo- and 5-[211At] astato-1-(2-deoxy-2-fluoro-D-arabinofuranosyl) uracil by a halodestannylation reaction. Nucl Med Biol 1998; 25:487-496
  12. Walicka MA, Vaidyanathan G, Zalutsky MR, Adelstein SJ, Kassis AI. Survival and DNA damage in V79 cells exposed to DNA-incorporated alpha particle emitter astatine-211. Radiation Res. 1998; 150:263-268
  13. Reist CJ, Bigner DD, Zalutsky MR. Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent. Clinical Cancer Res 1998; 4:2495-2502
  14. Vaidyanathan G, Zalutsky MR, DeGrado TR. Evaluation of iodopyridine for iodobenzene substitution for use with low-molecular weight radiopharmaceuticals: application to meta-iodobenzylguanidine. Bioconjugate Chem. 1998; 9:758-764
  15. Larsen RH, Vaidyanathan G, Zalutsky MR. The cytotoxicity of a-particle emitting 5-[211At]astato2'-deoxyuridine in human cancer cells. Int J Radiation Biol. 1997; 72:79-90
  16. Reist CJ, Archer GE, Wikstrand CJ, Bigner DD, Zalutsky MR. Improved targeting of an anti-EGFRvIII monoclonal antibody in tumor xenografts after labeling using N-succinimdyl 5-iodo-3-pyridinecarboxylate. Cancer Res., 1997; 57:1510-1515
  17. 4. Vaidyanathan, G., Larsen, R.H., and Zalutsky, M.R.:5-[211At]astato-2\'-deoxyuridine, an à-particle emitting endoradiotherapeutic agent undergoing DNA incorporation. Cancer Res. 1996; 56:1204-1209.
  18. 1. Vaidyanathan, G., Affleck, D.J., and Zalutsky, M.R.: No-carrier-added 4-fluoro-3-[131I]iodobenzylguanidine and 3-[211At]astato-4-fluorobenzylguanidine. Bioconjugate Chem., 1996; 7:102-107.
  19. 7. Vaidyanathan, G.V., Friedman, H.S., Keir, S.T., and Zalutsky, M.R.: Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity. Br. J. Cancer, 1996; 73:1171-1177.
  20. 10. Hauck, M.L., Dewhirst, M.W., and Zalutsky, M.R.: The effects of clinically relevant hyperthermic temperatures on the kinetic binding parameters of a monoclonal antibody. Nucl. Med. Biol., 1996; 23:551-557.
  21. 13. Vaidyanathan, G., Friedman, H.S., Keir, S.T., and Zalutsky, M.R.: Evaluation of Meta-[211At]astatobenzylguanidine in an athymic mouse human xenograft model. Nucl. Med. Biol, 1996; 23:851-856.
  22. 2. Larsen, R.H., Wieland, B.W., and Zalutsky, M.R.: Evaluation of an internal cyclotron target for the production of astatine-211 via the 209Bi(à,2n)211At reaction. Appl. Radiat. Isotop., 1996; 47:135-143.
  23. 3. Vaidyanathan, G., Larsen, R.H., and Zalutsky, M.R.: 5-[211At]astato-2'-deoxyuridine, an à-particle emitting endoradiotherapeutic agent undergoing DNA incorporation. Cancer Res. 1996; 56:1204-1209. 4. Garg, P.K., Alston, K.L., Welsh, P.C., and Zalutsky, M.R.: Enhanced binding and inertness to dehalogenation of à-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate. Bioconjugate Chem., 1996; 7:233-239.
  24. 5. Berry, C.R., Garg, P.K., DeGrado, T.R., Hellyer, P., Weber, W., Garg, S., Hansen, B., Zalutsky, M.R., and Coleman, R.E.: Para-[18F]fluorobenzylguanidine kinetics in a canine coronary artery occlusion model. J. Nucl. Cardiol., 1996; 3:119-129.
  25. 6. McLendon, R.E., Archer, G.E., Garg, P.K., Bigner, D.D., and Zalutsky, M.R.: Radiotoxicity of systemically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long term survival study with histologic analysis. Int. J. Radiat. Oncol. Biol. Phys., 1996; 35:69-80.
  26. 8. Brown, M.T., Coleman, R.E., Friedman, A.H., Friedman, H.S., McLendon, R.E., Reiman, R., Felsberg, G.J., Tien, R.D., Bigner, S.H., Zalutsky, M.R., Zhao, X.G., Wikstrand, C.J., Pegram, C.N., Herndon II, J.E., Vick, N.A., Paleologos, N., Fredericks, R.K., Schold, Jr., S.C., and Bigner, D.D.: Intrathecal 131I-labeled anti-tenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results. Clin. Cancer Res. 1996; 2:963-972.
  27. 9. Zalutsky, M.R., Archer, G.E., Garg, P.K., Batra, S.K., and Bigner, D.D.: Chimeric anti-tenascin antibody 81C6:increased tumor localization compared with its murine parent. Nucl. Med. Biol. 1996; 23:449-458.
  28. 11. Olafsen, T., Bruland, .S., Zalutsky, M.R., and Sandlie, I.: Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: applications to radiolabeling. Acta Oncologica, 1996; 35:297-301.
  29. 12. Zalutsky, M.R. and Bigner, D.D.: Radioimmunotherapy with à-particle emitting radio-immunoconjugates. Acta Oncologica, 1996; 35:373-379.
  30. 14. Reist, C.J., Garg, P.K., Alston, K.L., Bigner, D.D., and Zalutsky, M.R.: Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridine-carboxylate: in vitro studies. Cancer Res., 1996; 56:4970-4977.
  31. 15. Vaidyanathan, G. and Zalutsky, M.R.: Targeted therapy using alpha emitters. Physics Med. Biol., 1996; 41:1915-1931.
  32. 16. Zalutsky, M.R., Schuster, J.M., Garg, P.K., Archer, Jr., G.E., Dewhirst, M.W., and Bigner, D.D.: Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia. In: Recent Results in Cancer Research: Systemic Radiotherapy with Monoclonal Antibodies. Sautter-Bihl, M.-L., Bihl, H., and Wannenmacher, M., eds. Springer, Berlin, 1996; 141:101-122.
  33. 17. Bast, R.C., Jr., Zalutsky, M.R., and Frankel, A.: Monoclonal Serotherapy. In: Cancer Medicine, 4th edition. Holland, J.F., Frei III, E., Bast, R.C., Jr., Kufe, D.W., Morton, D.L., and Weichselbaum, R.R., eds., Williams and Wilkins, Baltimore, 1996; 1245-1262.
  34. 5. Reist, C.J., Garg, P.K., Alston, K.L., Bigner, D.D., and Zalutsky, M.R.: Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridine-carboxylate: in vitro studies. Cancer Res., 1996;56:4970-4977.
  35. 2. DeGrado, T.R., Zalutsky, M.R., and Vaidyanathan, G.: Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart. Nucl. Med. Biol. 1995; 22:1-12.
  36. 5. Vaidyanathan, G., Affleck, D.J., and Zalutsky, M.R.: Validation of 4-[18F]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J. Nucl. Med., 1995; 36:644-650
  37. 10. Garg, P.K., Alston, K.L., and Zalutsky, M.R.: Catabolism of radioiodinated murine monoclonal antibody F(ab')2 fragment labeled using N-succinimidyl 3-iodobenzoate and Iodogen methods. Bioconjugate Chem., 1995; 6:493-501.
  38. 12. Vaidyanathan, G., and Zalutsky, M.R.: Fluorine-18 labeled chemotactic peptides: a potential approach for the PET imaging of bacterial infection. Nucl. Med. Biol., 1995; 22:759-764.
  39. 14. Reist, C.J., Archer, G.A., Kurpad, S.N., Wikstrand, C.J., Vaidyanathan, G., Willingham, M.C., Wong, A.J., Bigner, D.D., and Zalutsky, M.R.: Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res., 1995; 55:4375-4382.
  40. Olafsen T, Brugland S, Zalutsky MR, Sandlie I. Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Location of lysine residues and implications for radiolabeling. Nucl Med Biol 1995; 22:765-772
  41. 1. Schuster, J.M., Zalutsky, M.R., Noska, M.A., Dodge, R., Friedman, H.S., Bigner, D.D., and Dewhirst, M.W.: Hyperthermic modulation of radiolabelled antibody uptake in a human glioma xenograft and normal tissues. Int. J. Hyperthermia 1995; 11:59-72.
  42. 3. Johnson, E.L., Turkington, T.G., Jaszczak, R.J., Vaidyanathan, G., Green, K.L., Coleman, R.E., and Zalutsky, M.R.: Quantitation of 211At in small volumes for evaluation of targeted radiotherapy in animal models. Nucl. Med. Biol. 1995; 22: 45-54.
  43. 4. Vaidyanathan, G., and Zalutsky, M.R.: No-carrier-added meta-[123I]iodobenzylguanidine: synthesis and preliminary evaluation. Nucl. Med. Biol. 1995;22:61-64.
  44. 6. Mairs, R.J., O'Donoghue, J.A., Russell, J., Cunningham, S., Gaze, M.N., Vaidyanathian, G., and Zalutsky, M.R.: Enhanced tumor uptake and in vitro radiotoxicity of no-carrier-added [131I]MIBG: implications for the targeted radiotherapy of neuroblastoma. Eur. J. Cancer, 1995; 31A:576-581.
  45. 7. Garg, P.K., John, C.S., and Zalutsky, M.R.: Preparation and preliminary evaluation of 4-[211At]astato-N-piperidinoethylbenzamide. Nucl. Med. Biol. 1995; 22:467-474.
  46. 8. Wikstrand, C.J., Hale, L.P., Batra, S.K., Hill, M.L., Humphrey, P.A., Kurpad, S.N., McLendon, R.E., Moscatello, D., Pegram, C.N., Reist, C.J., Traweek, S.T., Wong, A.J., Zalutsky, M.R., and Bigner, D.D.: Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res., 1995; 55:3140-3148.
  47. 9. Bigner, D.D., Brown, M., Coleman, R.E., Friedman, A.H., Friedman, H.S., McLendon, R.E., Bigner, S.H., Wikstrand, C.J., Pegram, C.N., Kerby, T., and Zalutsky, M.R.: Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F(ab')2 - A preliminary report. J. Neuro-Oncol. 1995; 24:109-122.
  48. 11. Olafsen, T., Bruland, .S., Zalutsky, M.R.,and Sandlie, I.: Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Location of lysine residues and implications for radiolabeling. Nucl. Med. Biol. 1995; 22:765-772.
  49. 13. Strickland, D.K., Vaidyanathan, G., Friedman, H.S., and Zalutsky, M.R.: Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines. J. Neuro-Oncol., 1995; 25:9-17.
  50. 15. Smellie, W.J.B., Dean, C.J., Sacks, N.P.M., Zalutsky, M.R., Garg, P.K., Carnochan, P., and Ecoles, S.A.: Radioimmunotherapy of breast cancer xenografts with monoclonal antibody ICR12 against c-erbB2 p185: comparison of iodogen and N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate radioiodination methods. Cancer Res. (Suppl.), 1995; 55:5842s-5846s. 16. Hauck, M.L., Dewhirst, M.W., and Zalutsky, M.R.: Local hyperthermia for enhancing the delivery of monoclonal antibodies. In: Targeted Delivery of Imaging Agents. Torchilin, V.P., ed., CRC Press, Boca Raton, FL, 1995; 335-361.
  51. 17. Zalutsky, M.R., Vaidyanathan, G., Garg, P.K., and Page, R.L.: Fluorine-18 labeled monoclonal antibodies for positron emission tomographic imaging. In: Targeted Delivery of Imaging Agents. Torchilin, V.P., ed., CRC Press, Boca Raton, FL, 1995; 665-691.
  52. 18. Mairs, R.J., and Zalutsky, M.R.: New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment. Letter to the Editor. Br. J. Cancer 1995; 72:250.
  53. 3. Garg S, Garg PK, Zhao XG, Friedman HS, Bigner DD, and Zalutsky MR. Radioiodination of a Monoclonal Antibody Using N-Succinmimidyl 5-Iodo-3-Pyridinecarboxylate. Nucl. Med. Biol. 1993; 20:835-842.
  54. 5. Bast RC Jr., Zalutsky MR and Frankel A. Monoclonal Antibodies. In: Cancer Medicine, 3rd edition. Holland JF, ed., Lea and Febiger, 1993; 968-982.
  55. 9. Jaszczak RJ, Li J, Wang H, Zalutsky M and Coleman RE. Pinhole Collimation for Ultra-High Resolution, Small Field-of-View SPECT. Phys. Med. Biol. 1994; 39:425-437.
  56. 11. Vaidyanathan G, Strickland DK and Zalutsky MR. Meta-[211At] Astatobenzylguanidine: Further Evaluation of a Potential Therapeutic Agent. Int. J. Cancer 1994; 57:908-913.
  57. 2. Zalutsky, M.R., McLendon, R., Garg, P.K., Archer, G.E., Schuster, J.M., and Bigner, D.D.: Radioimmunotherapy of neoplastic meningitis in rats using an à-particle-emitting immunoconjugate. Cancer Res. 1994;54:4719-4725.
  58. 3. Page, R.L., Garg, P.K., Garg, S., Archer, G.E., Bruland, .S., and Zalutsky, M.R.: Positron emission tomographic imaging of osteosarcoma in dogs using an 18F-labeled monoclonal antibody Fab fragment. J. Nucl. Med. 1994; 35:1506-1513.
  59. 1. Garg PK, Garg S, and Zalutsky MR. N-Succinimidyl-4-Methyl-3-(tri-n-butylistannyl) Benzoate: Synthesis, Radioiodination and Potential Utility for the Radioiodination of Monoclonal Antibodies. Nucl. Med. Biol. 1993; 20:379-388.
  60. 2. Schold SC Jr., Zalutsky MR, Coleman RE, Glantz MJ, Friedman AH, Jaszczak RJ, Bigner SH, and Bigner DD. Distribution and Dosimetry of I-123-Labeled Monoclonal Antibody 81C6 in Patients with Anaplastic Glioma. Invest. Radiol. 1993; 28:488-496.
  61. 4. Turkington TG, Zalutsky MR, Jaszczak RJ, Garg P, Vaidyanathan G, and Coleman RE. Measuring Astatine-211 Distributions with SPECT. Phys. Med. Biol. 1993; 38:1121-1130.
  62. 6. Vaidyanathan G, Affleck D. and Zalutsky MR. Monoclonal Antibody F(ab')2 Fragment Labeled with N-Sccinimidyl 2,4-Dimethoxy-3-Halobenzoates: In Vivo Comparison of Iodinated and Astatinated Fragments. Nucl Med Biol. 1994; 21:105-110.
  63. 7. Garg PK, Garg S, and Zalutsky MR. Synthesis and Preliminary Evaluation of para- and meta-[18F]Fluorobenzylguanidine. Nucl. Med. Biol. 1994; 21:97-104.
  64. 8. Mairs RJ, Gaze MN, Watson DG, Skellern GG, Constable P, McKellar K, Owens J, Vaidyanathan G, and Zalutsky MR. Synthesis of Carrier-Free 131I-meta-iodobenzlyguanidine by Novel Routes to Enhance Therapeutic Efficacy. Nucl. Med. Commun. 1994; 15:268-274.
  65. 10. Batra SK, Niswonger Ml, Wikstrand CJ, Pegram CN, Zalutsky MR, Morrison SL, and Bigner DD. Mouse/Human Chimeric Me1-14 Antibody: Genomic Cloning of the Variable Region Genes, Linkage to Human Constant Region Genes Expression, and Characterization. Hybridoma 1994; 13:87-97.
  66. 12. He X, Archer GE, Wikstrand CJ, Morrison SL, Zalutsky MR, Bigner DD, and Batra SK. Generation and Characterization of a Mouse/Human Chimeric Antibody Directed Against Extracellular Matrix Protein Tenascin. J Neuroimmunol. 1994; 52:127-137.
  67. 13. Vaidyanathan G, and Zalutsky MR. An Improved Synthesis of N-succinimidyl 4-[18F]Fluorobenzoate and Its Application to the Labeling of a Monoclonal Antibody Fragment. Bioconjugate Chem. 1994; 5:352-356.
  68. 1. Zalutsky, M.R., Garg, P.K., Friedman, H.S., and Bigner, D.D.: Labeling monoclonal antibodies and F(ab')2 fragments with the alpha particle emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proc. Natl. Acad. Sci. USA 1989;86:7149-7153.

Papers Published

  1. Liu, Wenge and Dreher, Matthew R. and Furgeson, Darin Y. and Peixoto, Katia V. and Yuan, Hong and Zalutsky, Michael R. and Chilkoti, Ashutosh, Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice, Journal of Controlled Release, vol. 116 no. 2 SPEC ISS (2006), pp. 170 - 178 [026]  [abs]
  2. Betre, Helawe and Liu, Wenge and Zalutsky, Michael R. and Chilkoti, Ashutosh and Kraus, Virginia B. and Setton, Lori A., A thermally responsive biopolymer for intra-articular drug delivery, Journal of Controlled Release, vol. 115 no. 2 (2006), pp. 175 - 182 [022]  [abs]
  3. Liu, Wenge and Dreher, Matthew R. and Chow, Dominic C. and Zalutsky, Michael R. and Chilkoti, Ashutosh, Tracking the in vivo fate of recombinant polypeptides by isotopic labeling, Journal of Controlled Release, vol. 114 no. 2 (2006), pp. 184 - 192 [001]  [abs]
  4. Boyd, M. and Ross, S.C. and Dorrens, J. and Fullerton, N.E. and Tan, K.W. and Zalutsky, M.R. and Mairs, R.J., Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with α, β, and auger electron-emitting radionuclides, J. Nucl. Med. (USA), vol. 47 no. 6 (2006), pp. 1007 - 15  [abs]
  5. Pozzi, O.R. and Zalutsky, M.R., Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 1: Effects of solvent on the degradation of radiohalogenation precursors by 211At α-particles, J. Nucl. Med. (USA), vol. 46 no. 4 (2005), pp. 700 - 6  [abs]
  6. Vaidyanathan, G. and Affleck, D.J. and Zalutsky, M.R., No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue, Appl. Radiat. Isot. (UK), vol. 62 no. 3 (2005), pp. 435 - 40 [001]  [abs]
  7. Hauck, M.L. and Zalutsky, M.R., Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II. Application of the thermal equivalency equation, Int. J. Hyperth. (UK), vol. 21 no. 1 (2005), pp. 13 - 27 [02656730400011032]  [abs]
  8. Hauck, M.L. and Zalutsky, M.R., Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part I. Timing of injection relative to hyperthermia, Int. J. Hyperth. (UK), vol. 21 no. 1 (2005), pp. 1 - 11 [02656730410001695906]  [abs]
  9. Zalutsky, M.R., Current status of therapy of solid tumors: brain tumor therapy, J. Nucl. Med. (USA), vol. 46 (2005), pp. 151S-6S -  [abs]
  10. Akabani, G. and McLendon, R.E. and Bigner, D.D. and Zalutsky, M.R., Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis, Int. J. Radiat. Oncol. Biol. Phys. (USA), vol. 54 no. 4 (2002), pp. 1259 - 75 [S0360-3016(02)03794-X]  [abs]
  11. Zalutsky, M.R. and Xiao-Guang Zhao and Alston, K.L. and Bigner, D., High-level production of α-particle-emitting 211At and preparation of 211At-labeled antibodies for clinical use, J. Nucl. Med. (USA), vol. 42 no. 10 (2001), pp. 1508 - 15  [abs]
  12. Meyer, Dan E. and Kong, Garheng A. and Dewhirst, Mark W. and Foulon, Catherine and Zalutsky, Michael R. and Chilkoti, Ashutosh, Genetically engineered polypeptide carrier for thermal targeting of anticancer therapeutics, American Chemical Society, Polymer Preprints, Division of Polymer Chemistry, vol. 41 no. 1 (2000), pp. 1020 - 1021, San Francisco, CA, USA  [abs]
  13. Aurlien, E. and Larsen, R.H. and Akabani, G. and Olsen, D.R. and Zalutsky, M.R. and Bruland, O.S., Exposure of human osteosarcoma and bone marrow cells to tumour-targeted α-particles and γ-irradiation: analysis of cell survival and microdosimetry, Int. J. Radiat. Biol. (UK), vol. 76 no. 8 (2000), pp. 1129 - 41 [09553000050111604]  [abs]
  14. Akabani, G. and Cokgor, I. and Coleman, R.E. and Trotter, D.G. and Wong, T.Z. and Friedman, H.S. and Friedman, A.H. and Garcia-Turner, A. and Herndon, J.E., II. and Delong, D. and McLendon, R.E. and Xiao-Guang Zhao and Pegram, C.N. and Provenzale, J.M. and Bigner, D.D. and Zalutsky, M.R., Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy, Int. J. Radiat. Oncol. Biol. Phys. (USA), vol. 46 no. 4 (2000), pp. 947 - 58 [S0360-3016(99)00500-3]  [abs]
  15. Akabani, G. and Reist, C.J. and Cokgor, I. and Friedman, A.H. and Friedman, H.S. and Coleman, R.E. and Xiao-Guang Zhao and Bigner, D.D. and Zalutsky, M.R., Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors, J. Nucl. Med. (USA), vol. 40 no. 4 (1999), pp. 631 - 8  [abs]
  16. Larsen, R.H. and Akabani, G. and Welsh, P. and Zalutsky, M.R., The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro, Radiat. Res. (USA), vol. 149 no. 2 (1998), pp. 155 - 62  [abs]
  17. Akabani, G. and Zalutsky, M.R., Microdosimetry of astatine-211 using histological images: application to bone marrow, Radiat. Res. (USA), vol. 148 no. 6 (1997), pp. 599 - 607  [abs]
  18. Vaidyanathan, G. and Zalutsky, M. R., A New Route to Guanidines from Bromoalkanes, Journal of Organic Chemistry, vol. 62 no. 14 (1997), pp. 4867 - [jo9704164]
  19. Larsen, R.H. and Vaidyanathan, G. and Zalutsky, M.R., Cytotoxicity of α-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells, Int. J. Radiat. Biol. (UK), vol. 72 no. 1 (1997), pp. 79 - 90 [095530097143563]  [abs]
  20. Hauck, M.L. and Coffin, D.O. and Dodge, R.K. and Dewhirst, M.W. and Mitchell, J.B. and Zalutsky, M.R., A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure, Int. J. Hyperth. (UK), vol. 13 no. 3 (1997), pp. 307 - 16  [abs]
  21. Vaidyanathan, G. and Zalutsky, M.R., Targeted therapy using alpha emitters, Phys. Med. Biol. (UK), vol. 41 no. 10 (1996), pp. 1915 - 31 [005]  [abs]
  22. Vaidyanathan, G. and Affleck, D. J. and Slade, S. A. and Zalutsky, M. R., Labeling of Monoclonal Antibodies (MAbs) with N-Succinimidyl 3-hydroxy-4-[131I]iodobenzoate (mSHIB), Journal of Labelled Compounds and Radiopharmaceuticals (1996), pp. 536 -
  23. Zalutsky, M.R. and Bigner, D.D., Radioimmunotherapy with α-particle emitting radioimmunoconjugates, Acta Oncologica, vol. 35 no. 3 (1996), pp. 373 -, Lillehammer, Norway
  24. Garg, P. K. and Alston, K. L. and Zalutsky, M. R., Catabolism of Label from an F(ab')2 Fragment Radioiodinated Using N-Succinimidyl 3-iodobenzoate and Iodogen Methods, Journal of Labelled Compounds and Radiopharmaceuticals (1996), pp. 539 -
  25. Garg, P. K. and Alston, K. L. and Welsh, P. C. and Zalutsky, M. R., Preliminary Evaluation of Radioiodinated Alpha-melanocyte Stimulating Hormone (a-MSH) and its Analogue Using N-succinimidyl 3-iodobenzoate and Iodogen Methods, Journal of Labelled Compounds and Radiopharmaceuticals (1996), pp. 496 -
  26. Olafsen, T. and Bruland, O.S. and Zalutsky, M.R. and Sandlie, I., Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3 - application to radiolabeling, Acta Oncologica, vol. 35 no. 3 (1996), pp. 297 -, Lillehammer, Norway
  27. McLendon, R.E. and Archer, G.E. and Garg, P.K. and Bigner, D.D. and Zalutsky, M.R., Radiotoxicity of systemically administered [211At]astatide in B6C3F1 and BALB/c (NU/NU) mice: a long-term survival study with histologic analysis, Int. J. Radiat. Oncol. Biol. Phys. (USA), vol. 35 no. 1 (1996), pp. 69 - 80 [S0360-3016(96)85013-9]  [abs]
  28. Larsen, R.H. and Weiland, B.W. and Zalutsky, M.R., Evaluation of an internal cyclotron target for the production of 211At via the 209Bi(α,2n)211At reaction, Appl. Radiat. Isot. (UK), vol. 47 no. 2 (1996), pp. 135 - 43 [0969-8043(95)00285-5]  [abs]
  29. Schuster, J.M. and Zalutsky, M.R. and Noska, M.A. and Dodge, R. and Friedman, H.S. and Bigner, D.D. and Dewhirst, M.W., Hyperthermic modulation of radiolabelled antibody uptake in a human glioma xenograft and normal tissues, Int. J. Hyperth. (UK), vol. 11 no. 1 (1995), pp. 59 - 72  [abs]
  30. Jaszczak, R.J. and Jianying Li and Huili Wang and Zalutsky, M.R. and Coleman, R.E., Pinhole collimation for ultra-high-resolution, small-field-of-view SPECT, Phys. Med. Biol. (UK), vol. 39 no. 3 (1994), pp. 425 - 37, Snowbird, UT, USA [010]  [abs]
  31. Vaidyanathan, Ganesan and Zalutsky, Michael R., No-carrier-added synthesis of meta-[131I]iodobenzylguanidine, Applied Radiation and Isotopes, vol. 44 no. 3 (1993), pp. 621 - 628 [0969-8043(93)90179-E]  [abs]
  32. Turkington, T.G. and Zalutsky, M.R. and Jaszczak, R.J. and Garg, P.K. and Vaidyanathan, G. and Coleman, R.E., Measuring astatine-211 distributions with SPECT, Phys. Med. Biol. (UK), vol. 38 no. 8 (1993), pp. 1121 - 30 [010]  [abs]
  33. Fuchs, Herbert E. and Zalutsky, Michael R. and Archer, Gary E. and Bigner, Darell D., Diagnosis and therapy of brain tumors utilizing radiolabeled monoclonal antibodies, Texas A & M University, IUCCP Symposium on Applications of Enzyme Biotechnology (1991), pp. 29 -, College Station, TX, USA
  34. Zalutsky, Michael R. and Garg, Pradeep K. and Vaidyanathan, Ganesan and Garg, Sudha, Methods for the radiohalogenation of antibodies, Texas A & M University, IUCCP Symposium on Applications of Enzyme Biotechnology (1991), pp. 15 -, College Station, TX, USA
  35. Garg, Pradeep K. and Archer, Gerald E. Jr. and Bigner, Darell D. and Zalutsky, Michael R., Synthesis of radioiodinated N-succinimidyl iodobenzoate. Optimization for use in antibody labelling, Applied Radiation and Isotopes, vol. 40 no. 6 (1989), pp. 485 - 490 [0883-2889(89)90131-7]  [abs]
  36. Zalutsky, Michael R. and Narula, Acharan S., ASTATINATION OF PROTEINS USING AN N-SUCCINIMIDYL TRI-n-BUTYLSTANNYL BENZOATE INTERMEDIATE., Applied Radiation and Isotopes, vol. 39 no. 3 (1988), pp. 227 - 232 [0883-2889(88)90176-1]  [abs]
  37. Bloomer, W.D. and McLaughlin, W.H. and Lambrecht, R.M. and Atcher, R.W. and Mirzadeh, S. and Madara, J.L. and Milius, R.A. and Zalutsky, M.R. and Adelstein, S.J. and Wolf, A.P., 211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90Y, Int. J. Radiat. Oncol. Biol. Phys. (UK), vol. 10 no. 3 (1984), pp. 341 - 8  [abs]
  38. Zalutsky, M.R. and Macias, E.S. and Meyer, R.A., Structure of N=81 nuclei: Levels of 141Nd and 139Ce populated in beta decay, Phys. Rev. C, Nucl. Phys. (USA), vol. 13 no. 4 (1976), pp. 1590 - 600 [1590]  [abs]
  39. Zalutsky, M.R. and Macias, E.S., Angular correlation of X-rays: L-M cascades of plutonium, Phys. Rev. A, Gen. Phys. (USA), vol. 12 no. 2 (1975), pp. 526 - 30 [526]  [abs]
  40. Zalutsky, M.R. and Macias, E.S., Comparison of techniques for the determination of the L2-L3X Coster-Kronig transition probability, Phys. Rev. A, Gen. Phys. (USA), vol. 11 no. 3 (1975), pp. 1093 - 6 [1093]  [abs]
  41. Zalutsky, M.R. and Macias, E.S. and Catz, A.L., Angular correlation between K and L X-rays in tantalum, Phys. Rev. A, Gen. Phys. (USA), vol. 11 no. 1 (1975), pp. 75 - 8 [75]  [abs]
  42. Zalutsky, M.R. and Macias, E.S., External determination of the L2-L3X Coster-Kronig transition probability in europium, plutonium, and curium, Phys. Rev. A, Gen. Phys. (USA), vol. 11 no. 1 (1975), pp. 71 - 4 [71]  [abs]
  43. Macias, E.S. and Head, R.E. and Hseuh, H.-C. and Zalutsky, M.R., On-line determination of transport time of a helium-jet system, Nucl. Instrum. Methods (Netherlands), vol. 122 no. 3 (1974), pp. 365 - 8  [abs]
  44. Macias, E.S. and Zalutsky, M.R., K-L X-ray angular correlations in Cm, Pu and Eu, Phys. Rev. A, Gen. Phys. (USA), vol. 9 no. 6 (1974), pp. 2356 - 64 [2356]  [abs]
  45. Zalutsky, M.R. and Macias, E.S., Measurement of the angular correlation between L-M X-ray cascades, Phys. Lett. A (Netherlands), vol. 49A no. 4 (23), pp. 285 - 6  [abs]
  46. McLendon, R.E. and Archer, G.E. and Larsen, R.H. and Akabani, G. and Bigner, D.D. and Zalutsky, M.R., Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis, Int. J. Radiat. Oncol. Biol. Phys. (USA), vol. 45 no. 2 (1), pp. 491 - 9 [S0360-3016(99)00206-0]  [abs]
  47. Walicka, M.A. and Vaidyanathan, G. and Zalutsky, M.R. and Adelstein, S.J. and Kassis, A.I., Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211, Radiat. Res. (USA), vol. 150 no. 3 , pp. 263 - 8  [abs]
  48. Zalutsky, M.R. and Macias, E.S., Decay of 5.8 min 140Pmm and 10-sec 140Pmg to levels of 140Nd, Phys. Rev. C, Nucl. Phys. (USA), vol. 12 no. 3 , pp. 997 - 1002 [997]  [abs]
  49. Zalutsky, M.R. and Macias, E.S., Search for an anisotropy between Lℒ X-rays and γ rays in the decay of 243Cm, Phys. Rev. C, Nucl. Phys. (USA), vol. 12 no. 3 , pp. 1076 - 9 [1076]  [abs]
Duke University * Pratt * Reload * Login